At GBS, we're focused on one and only one mission: to help talented entrepreneurs build great life science technology companies.

Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety

25 / 06 / 2026

> Read More

Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

28 / 05 / 2026

> Read More

Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

25 / 11 / 2025

> Read More